Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 6/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 5/20 | 0.33 |
| ▸ | RAB9A | P51151 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | EDNRA | P25101 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5385435 | 0.88 | POLB (0.38) | POLBMAPTSMN1; SMN2TP53TSHR | |
| SCHEMBL5387906 | 0.88 | KMT2A (0.43) | POLBMAPTSMN1; SMN2TP53TSHR | |
| SCHEMBL5379348 | 0.87 | CYP3A4 (0.36) | POLBMAPTSMN1; SMN2TP53TSHR | |
| SCHEMBL14337944 | 0.87 | CYP3A4 (0.36) | POLBMAPTSMN1; SMN2TP53TSHR | |
| SCHEMBL14337992 | 0.86 | EGFR (0.36) | POLBMAPTSMN1; SMN2TSHRRAB9A | |
| SCHEMBL14337870 | 0.85 | RAB9A (0.35) | POLBMAPTSMN1; SMN2TP53TSHR | |
| SCHEMBL14338000 | 0.84 | POLB (0.34) | POLBMAPTSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL14350683 | 0.84 | POLB (0.40) | POLBMAPTSMN1; SMN2TP53TSHR | |
| SCHEMBL14337997 | 0.84 | HPGD (0.33) | POLBMAPTSMN1; SMN2TSHRNPC1 | |
| SCHEMBL5376446 | 0.84 | CYP3A4 (0.39) | POLBSMN1; SMN2CYP3A4ALOX15NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312347-B2 | Substituted optically active disphosphine compound | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-12-25 | — | — | US | disclosed |
| US-7312347-B2 | Substituted optically active disphosphine compound | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-12-25 | — | — | US | disclosed |
| US-7312347-B2 | Substituted optically active disphosphine compound | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-12-25 | — | — | US | disclosed |
| US-20070073065-A1 | Substituted optically active disphosphine compound | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-03-29 | — | — | US | disclosed |
| US-20070073065-A1 | Substituted optically active disphosphine compound | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-03-29 | — | — | US | disclosed |
| US-20070073065-A1 | Substituted optically active disphosphine compound | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070073065-A1 | Substituted optically active disphosphine compound | DHPS, DOHH, DHODH | POLB 2201/4885MAPT 4288/4885SMN1; SMN2 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.